Attributes | Values |
---|
rdf:type
| |
rdfs:seeAlso
| |
Description
| - Patients with core binding factor acute myeloid leukemia (CBF-AML) benefit from more intensive chemotherapy, but whether both the t(8;21) and inv(16)/t (16;16) sub-types requires intensification remained to be determined. In the 2 successive studies (AML-BFM-1998 and AML-BFM-2004), 220 CBF-AML patients were treated using the same chemotherapy backbone, whereby reinduction with high-dose cytarabine and mitoxantrone (HAM) was scheduled for these cohorts only in study AML-BFM-1998 but not in AML-BFM-2004 against the background to minimize over-treatment. Five-year overall survival (OS) and event-free survival (EFS) were significantly higher and the cumulative incidence of relapse (CIR) lower in t(8;21) patients treated with HAM (n = 78) compared with without HAM (n = 53): OS 92% +/- 3% versus 80% +/- 6%, p(logrank)0.047, EFS 84% +/- 4% versus 59% +/- 7%, p(logrank)0.001, and CIR 14% +/- 4% versus 34% +/- 7%, p((gray)) 0.006. These differences were not seen for inv(16) (n = 43 and 46, respectively): OS 93% +/- 4% versus 94% +/- 4%, EFS 75% +/- 7% versus 71% +/- 9% and CIR 15% +/- 6% versus 23% +/- 8% (not significant). The subtype t(8; 21), but not inv(16), was an independent predictor of worse outcome without HAM reinduction. Based on our data, a 5-year OS of > 90% can be expected for CBF-AML, when stratifying t(8;21), but not inv(16), patients to high-risk chemotherapy, including HAM reinduction
- Patients with core binding factor acute myeloid leukemia (CBF-AML) benefit from more intensive chemotherapy, but whether both the t(8;21) and inv(16)/t (16;16) sub-types requires intensification remained to be determined. In the 2 successive studies (AML-BFM-1998 and AML-BFM-2004), 220 CBF-AML patients were treated using the same chemotherapy backbone, whereby reinduction with high-dose cytarabine and mitoxantrone (HAM) was scheduled for these cohorts only in study AML-BFM-1998 but not in AML-BFM-2004 against the background to minimize over-treatment. Five-year overall survival (OS) and event-free survival (EFS) were significantly higher and the cumulative incidence of relapse (CIR) lower in t(8;21) patients treated with HAM (n = 78) compared with without HAM (n = 53): OS 92% +/- 3% versus 80% +/- 6%, p(logrank)0.047, EFS 84% +/- 4% versus 59% +/- 7%, p(logrank)0.001, and CIR 14% +/- 4% versus 34% +/- 7%, p((gray)) 0.006. These differences were not seen for inv(16) (n = 43 and 46, respectively): OS 93% +/- 4% versus 94% +/- 4%, EFS 75% +/- 7% versus 71% +/- 9% and CIR 15% +/- 6% versus 23% +/- 8% (not significant). The subtype t(8; 21), but not inv(16), was an independent predictor of worse outcome without HAM reinduction. Based on our data, a 5-year OS of > 90% can be expected for CBF-AML, when stratifying t(8;21), but not inv(16), patients to high-risk chemotherapy, including HAM reinduction (en)
|
Title
| - Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)
- Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) (en)
|
skos:prefLabel
| - Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)
- Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) (en)
|
skos:notation
| - RIV/00064203:_____/11:7274!RIV12-MZ0-00064203
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00064203:_____/11:7274
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - acute myeloid-leukemia; group-b; prognostic-significance; children; cancer; mutations; therapy; trial; kit; intensification (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Bourquin, J. P.
- Creutzig, U.
- Dworzak, MN
- Reinhardt, D.
- Sander, A.
- Schrauder, A.
- Starý, Jan
- Zimmermann, M.
- von Neuhoff, C.
- Corbacioglu, S.
- Teigler-Schlegel, A.
|
http://linked.open...ain/vavai/riv/wos
| |
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |